Search | Clinical Trials Finder

Conditions: Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions: Biospecimen Collection, Cobimetinib, Computed Tomography, Diagnostic Imaging, I-131 Uptake Test, Iodine I-131, Magnetic Resonance Imaging, Positron Emission Tomography, Recombinant Thyrotropin Alfa, Ultrasound Imaging, Vemurafenib; Procedure · Drug · Radiation + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Infertility
Interventions: Bravelle, Menopur; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Lone Tree, Colorado • Clearwater, Florida • Atlanta, Georgia + 7 more

Conditions: Infertility, Obesity
Interventions: Follicle Stimulating Hormone; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 19 Years to 37 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Ovarian Cancer
Interventions: Follicle Stimulating Hormone Receptor T Cells; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hypogonadotropic Hypogonadism
Interventions: Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Infertility
Interventions: Clomiphene Citrate; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1991 – 1994
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Infertility, Female
Interventions: Follitropin delta, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 35 Years to 42 Years · Female only
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Tempe, Arizona • Encino, California • Farmington, Connecticut + 21 more

Conditions: Infertility
Interventions: follitropin beta, ganirelix acetate; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 20 Years to 42 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Infertility, Reproductive Techniques, Assisted
Interventions: IVM media, Follicle Stimulating Hormone (FSH); Device · Drug
Lead sponsor: National Foundation for Fertility Research; Other
Eligibility: 21 Years to 35 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Lone Tree, Colorado

Conditions: Infertility
Interventions: Low dose hCG plus FSH co-trigger, Standard dose of hCG; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 41 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Infertility
Interventions: Follitropin delta, Placebo; Drug · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Tempe, Arizona • Encino, California • Farmington, Connecticut + 20 more

Conditions: Infertility, Hypothalamic Amenorrhea, Hyperprolactinemia
Interventions: Luveris fixed dose, Luveris increasing dose; Drug
Lead sponsor: University Reproductive Associates; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Hasbrouck Heights, New Jersey

Conditions: Infertility, Diminished Ovarian Reserve, IVF
Interventions: Timing of injectable gonadotropins; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Compare Pregnancy Rates Between FSH Stimulation and FSH and, GnRH Antagonist
Interventions: Follistim administration, Follistim plus Ganirelix; Drug
Lead sponsor: Houston Fertility Institute; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Infertility
Interventions: Letrozole; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Years to 45 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: laboratory biomarker analysis, fertility assessment and management, management of therapy complications, ultrasound imaging; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 14 Years to 35 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Infertility
Interventions: AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 36 Years · Female only
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Healthy, Fragile X Syndrome
Interventions: Follicle Aspiration; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib; Biological · Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 94
States / cities: Gilbert, Arizona • Tucson, Arizona • Duarte, California + 77 more

Conditions: Atrophic Vaginitis, Breast Cancer
Interventions: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions: therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer
Interventions: Decitabine, Iodine I 131, Recombinant thyrotropin alfa, Fludeoxyglucose F 18, Positron emission tomography; Drug · Radiation · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 3
States / cities: Aurora, Colorado • Columbus, Ohio • Houston, Texas

Conditions: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions: filgrastim, sargramostim, carmustine, cyclophosphamide, cytarabine, etoposide, leucovorin calcium, methotrexate, perfosfamide, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: Up to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2003
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cortical Excitability, Healthy, TMS, Menstrual Cycle, Menopause
Interventions: Transcranial Electrical Stimulation, Transcranial Magnetic Stimulation, TES + TMS; Device
Lead sponsor: Carnegie Mellon University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Menopur Mixed Protocol

Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])

Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)

Luteal Phase FSH in the IVF Poor Responder

In Vitro Maturation of Human Eggs

Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)

The Luveris In Vitro Fertilization Trial

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles

RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF

Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

Assessing the Effects of Hormones on Noninvasive Transcranial Stimulation